Proteostasis Therapeutics, Inc.
200 Technology Square
Suite 402
Cambridge
Massachusetts
02139
United States
Website: http://www.proteostasis.com/
Email: info@proteostasis.com
117 articles about Proteostasis Therapeutics, Inc.
-
Proteostasis Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference
12/3/2019
Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that Proteostasis management will present at the Piper Jaffray 31st Annual Healthcare Conference on Thursday
-
Proteostasis Therapeutics Regains Compliance with Nasdaq Listing Standards
12/2/2019
Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that it received a letter dated November 27, 2019 from the Listing Qualifications Department of The Nasdaq Stock Market LLC
-
Clinical Catch-Up: November 4-8
11/11/2019
It was a busy week for clinical trial updates for the first week of November. Here’s a look. -
Proteostasis Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
11/7/2019
Proteostasis Therapeutics, Inc. announced financial results for the third quarter ended September 30, 2019 and provided a corporate update.
-
Proteostasis Therapeutics Announces Completion of Enrollment in Global Phase 2 Study in Cystic Fibrosis
11/6/2019
Company Now Expects Phase 2 Top-line Data Later in Q4 of 2019 Instead of Q1 2020 Due to Rapid Enrollment
-
Proteostasis Therapeutics Announces Presentations Highlighting its CFTR Modulators at the North American Cystic Fibrosis Conference
10/24/2019
Proteostasis Therapeutics, Inc. announced that the Company's cystic fibrosis transmembrane conductance regulator modulators will be highlighted in five presentations at the North American Cystic Fibrosis Conference from October 31 – November 2, 2019 at the Nashville Music City Center in Nashville, Tennessee.
-
Proteostasis Therapeutics to Host Cystic Fibrosis Summit on Disparity in Access to CFTR Modulators Based on Geography Featuring Members of the Cystic Fibrosis Community and Thought Leaders
10/21/2019
Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis and other diseases caused by dysfunctional protein processing, announced that the Company will host a Cystic Fibrosis Summit.
-
Proteostasis Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
9/26/2019
Proteostasis Therapeutics, Inc. announced that Proteostasis management will present at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019 at 8:55 a.m. ET at the InterContinental New York Barclay.
-
Proteostasis Therapeutics Announces Presentation at the UK Cystic Fibrosis Conference
9/19/2019
Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that Proteostasis management will present at the UK Cystic Fibrosis Conference (UKCFC) on September 26-27, 2019 at the Kia Oval in Kennington, London, England.
-
Proteostasis Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
8/7/2019
Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced financial results for the second quarter ended June 30, 2019 and provided a corporate update.
-
Proteostasis Therapeutics Initiates Dosing in Global Phase 2 Study in Cystic Fibrosis
7/25/2019
Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis, announced that the first patient has been dosed in the Company's 28-day, Phase 2 study evaluating its proprietary cystic fibrosis transmembrane conductance regulator modulator combinations in F508del homozygous and heterozygous CF subjects.
-
Proteostasis Therapeutics Announces Management Changes and Appointments
7/23/2019
Proteostasis Therapeutics, Inc. announced the appointment of Geoffrey S. Gilmartin, M.D., M.M.Sc., as its Chief Medical Officer (CMO), and Andrey E. Belous, M.D., Ph.D., as a Senior Medical Director, effective August 5, 2019.
-
Proteostasis Therapeutics Receives Orphan Drug Designation in the EU for PTI-428 for the Treatment of Cystic Fibrosis
6/4/2019
Proteostasis Therapeutics, Inc. announced that the European Commission has granted orphan drug designation to PTI-428 for the treatment of cystic fibrosis.
-
Proteostasis Therapeutics Announces Presentations and Hosts Educational Symposium at the 42nd European Cystic Fibrosis Conference
6/3/2019
Proteostasis Therapeutics, Inc. announced that data from the Company's CF clinical development programs will be presented during three panel presentations at the 42nd European Cystic Fibrosis Society Conference on June 5-8, 2019 at the Arena and Convention Centre Liverpool in Liverpool, United Kingdom.
-
Proteostasis Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference
5/15/2019
Proteostasis Therapeutics, Inc. announced that Proteostasis management will present at the 2019 RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019 at 9:00 a.m. ET at the InterContinental New York Barclay.
-
Proteostasis Therapeutics Appoints Dr. Badrul Chowdhury, Former FDA Director of Pulmonology, Allergy, and Rheumatology, to Board of Directors
5/13/2019
Proteostasis Therapeutics, Inc. announced that Badrul A. Chowdhury, M.D., Ph.D., has been appointed to the Company's Board of Directors.
-
Proteostasis Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
5/8/2019
Proteostasis is a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis and other diseases caused by dysfunctional protein processing
-
Proteostasis Therapeutics Announces Broad New Dataset from Proprietary Combination and Add-On CFTR Modulator Studies in Cystic Fibrosis Patients
3/25/2019
Greatest ppFEV1 Improvement Shown in High Dose Triplet with Mean Absolute Improvement in ppFEV1 of 8 Percentage Points at 14 Days Compared to Placebo (p<0.05) in Subjects with Two F508del Mutations (F/F) Not Predisposed to Rapid Pulmonary Decline
-
Proteostasis Therapeutics Appoints David Arkowitz to Board of Directors
3/7/2019
Proteostasis Therapeutics, Inc. today announced that David Arkowitz has been appointed to the Company's Board of Directors. Mr. Arkowitz is the Chief Financial Officer (CFO) and Treasurer of Flexion Therapeutics, a publicly traded, commercial stage biotechnology company.
-
BioSpace gathered together a roundup of global biopharma news from the past week. Bayer and Orion Corporation, Themis Bioscience, Axonics Modulation Technologies, and more are mentioned in this edition.